Recent news on Remicade

Long-term ulcerative colitis study shows Remicade responders ...  -  25 May 2007
News-Medical.net,..."The data demonstrate the sustained efficacy of REMICADE for many patients with UC," said co-principle investigator Walter Reinisch, MD, of the University

Harvard's Fishman Leads New Drug Strategy at Novartis (Update3)  -  25 May 2007
BloombergAmgen Inc.'s Enbrel brought in $1.18 billion in the period, and Johnson & Johnson received $1.1 billion in revenue from Remicade.

PDL Announces More Data  -  May 22, 2007
Motley FoolThat doesn't mean that looking at how Remicade performed in its long-term study can't give an indication of Nuvion's level of efficacy, after PDL released

Abbott Laboratories' Humira Will Replace Centocor's Remicade as ...  -  May 9, 2007
PR Newswire (press release),According to the new report entitled Humira Emerges as the Leading Therapy: A Crohn's Disease Study, Humira outperforms Remicade in efficacy, safety,

Enbrel, Remicade, and Humira Have Dramatically Transformed the ...  -  Apr 30, 2007
PR Newswire (press release),...the TNF-alpha inhibitors Enbrel, Remicade, and Humira have emerged over the past five years as highly effective treatments for psoriatic arthritis in

Royalty Pharma Acquires a Portion of New York University's Royalty ...  -  May 4, 2007
PR Newswire (press release),NYU received $650 million in cash up-front plus additional payments should yearly sales of Remicade(R) exceed certain agreed sales hurdles.

Royalty Pharma Acquires a Portion of New York University's Royalty ...  -  May 4, 2007
Earthtimes.orgNEW YORK, May 4 -- Royalty Pharma and New York University announced today that NYU has sold a portion of NYU's worldwide royalty interest in Remicade(R) to

Priced out of pain relief  -  May 8, 2007
San Francisco Chronicle,Her doctor has recommended increasing her dosage of Remicade, an intravenous drug used to treat inflammatory conditions. But Wild, who is covered by her

Study IDs Crohn's disease therapy  -  May 2, 2007
United Press International..."Approximately 50 percent of Crohn's disease patients ... will eventually develop an allergic reaction (to Remicade), need higher doses, or stop responding

Australian biotechs Peptech and EvoGenix set to merge  -  May 9, 2007
Pharma Times (subscription),Johnson & Johnson in relation to their respective blockbuster antibody anti-tumour necrosis factor drugs Humira (adalimumab) and Remicade (infliximab).

Cimzia's setback paves way for other TNF inhibitors in Crohn's disease  -  Apr 30, 2007
Nature.com (subscription),Neither Remicade nor Humira were subjected to such a rigorous design, he adds. A second study, also of six months' duration, is directly comparable to

Deal takes pep out of PepTech shares  -  May 7, 2007
The Age,Peptech gets royalties from its intellectual property in two drugs, Remicade, produced by Johnson & Johnson, and Humira, which Abbott Laboratories produces.

$650-Million to NYU From Drug Rights  -  May 14, 2007
Chronicle of Higher Education (subscription)...of its future royalty rights from sales of a drug called Remicade, which is used to fight rheumatoid arthritis and several other autoimmune diseases.

New Therapy For Patients With Crohn's Disease Identified By ...  -  May 7, 2007
Medical News Today (press release),Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE®) therapy.

News, Views and Careers for All of Higher Education  -  May 7, 2007
Inside Higher Ed,New York University and Royalty Pharma announced a deal under which NYU sold a portion of its royalty rights for the drum Remicade to the company for $650

Former Building Cleaner Confronts J&J About Access to Health Care ...  -  Apr 26, 2007
PR Newswire (press release),Nunez suffers from rheumatoid arthritis, a disease that can be treated with Remicade, a medication Centocor manufactures.

Researchers Identify New Therapy for Crohn's Disease  -  May 3, 2007
EndoNurse,Clinic found that adalimumab (HUMIRA®) is an effective treatment for adults with Crohn’s disease who do not respond to infliximab (REMICADE®) therapy.

Researchers Identify New Therapy for Patients with Crohn's Disease  -  May 3, 2007
DG NewsClinic found that adalimumab (HUMIRA®) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE®) therapy.

Researchers Identify New Therapy for Patients with Crohn’s Disease  -  May 1, 2007
Newswise (press release)Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn’s disease who do not respond to infliximab (REMICADE®) therapy.

Mayo Clinic News Release: Researchers Identify New Therapy for ...  -  May 1, 2007
PharmaLive.com (press release),Remicade (infliximab) is a product of Centocor, Inc. http://www.mayoclinic.org/news2007-rst/4047.html?src=email-release.

Infliximab Fails Test in Two Rheumatologic Diseases  -  Apr 30, 2007
MedPage Today,Explain that these studies tested infliximab (Remicade) a monoclonal antibody against tumor necrosis factor-alpha, and found it had no benefit and might

NYU sues drug company over patent  -  Apr 26, 2007
NYU Washington Square News,The co-plaintiffs claim that Abbott's top-selling drug, Humira, uses the same technology that was patented in July 2006 for their drug Remicade,

Abbott: Experimental psoriasis drug cleared skin  -  May 4, 2007
Chicago Tribune,Humira and the experimental drug are protein-based, and would compete with Johnson & Johnson's Remicade and Wyeth's Enbrel.

Infliximab Shows No Benefit in COPD  -  May 2, 2007
MedPage Today,OMAHA, Neb., May 2 -- Infliximab (Remicade), the tumor necrosis-factor alpha inhibitor, has proved ineffective for moderate to severe chronic obstructive

Crohn's sufferers seeking drug subsidy  -  Apr 26, 2007
The Age,...advisory body has recommended sufferers of severe Crohn's disease be given access to the expensive drug Infliximab, also known as Remicade.

Abbott's Humira extends reach with EU Crohn's okay  -  Apr 27, 2007
Therapeutics Daily (subscription) (press release),...by the European Commission within a couple of months. Humira will provide an alternative to Johnson & Johnson's drug Remicade for patients with Crohn's.

Former Building Cleaner Confronts J&J About Access to Health Care ...  -  26 Apr 2007
PR-Inside.com (Pressemitteilung),Nunez suffers from rheumatoid arthritis, a disease that can be treated with Remicade, a medication Centocor manufactures.

Crohn's sufferers seeking drug subsidy  -  26 Apr 2007
Sydney Morning Herald,...advisory body has recommended sufferers of severe Crohn's disease be given access to the expensive drug Infliximab, also known as Remicade.

Crippling at any age  -  26 Apr 2007
SalemNews.com,Every two weeks, Abbie has to go to Children's Hospital for an infusion of Remicade, one of a new class of drugs known as tumor necrosis factor blockers.

Spending on biotech drug prescriptions rising  -  26 Apr 2007
Scientific AmericanTop drugs included $2.7 billion for Johnson & Johnson's Remicade for arthritis, and $3.7 billion for Celgene Corp.'s cancer drug Thalomid.

Drug firm's profit jumps on demand for Remicade  -  Apr 20, 2007
Toronto Star,...its first-quarter profit rose 55 per cent to easily beat Wall Street expectations, helped by strong demand for its Remicade drug and other products.

Enbrel Prescribed More Widely than Remicade, According to a New ...  -  Apr 18, 2007
PR Newswire (press release),CNTO-1275 attains the position of clinical gold-standard therapy by 2015 because, relative to Remicade, it has demonstrated comparable efficacy on psoriatic

Despite Superior Efficacy on Psoriatic Plaque Clearance, Centocor ...  -  Apr 18, 2007
PR-Inside.com (Pressemitteilung),...position of clinical gold-standard therapy by 2015 because, relative to Remicade, it has demonstrated comparable efficacy on psoriatic plaque clearance and

Pinegar sentenced to 33 months in prison  -  Apr 22, 2007
Alva Review Courier,Through his plea, Pinegar has admitted that he intentionally submitted false claims to Medicare for two prescription medications: Procrit and Remicade.

REMICADE(R) Receives Approval in European Union for Dosing ...  -  Mar 30, 2007
Drug Newswire (press release),For patients who had an incomplete response to initial combination treatment with methotrexate and REMICADE 3 mg/kg, the dose titration label extension will

SP delivers again, beating forecasts  -  Apr 20, 2007
Pharma Times (subscription),Sales of Remicade (infliximab) increased 34% to $373 million, driven by growth across all indications. Remicade is a treatment for immune-mediated

Schering-Plough 1Q profit up 55 percent  -  Apr 19, 2007
BusinessWeekSales of Remicade increased 34 percent to $373 million, driven by continued market growth and expanded indications for its use. Remicade is a treatment for

[FULL STORY]  -  Apr 19, 2007
Advertiser,Shortly after his accident, he found out provincial government was no longer going to pay for his Remicade, a drug that helps manage his Crohn’s disease.

Former Alva doctor sentenced to prison for Medicare fraud  -  Apr 20, 2007
KTEN,Procrit is used to treat anemia and Remicade is used to treat Crohn's disease and rheumatoid arthritis. Prosecutors say Pinegar billed Medicare for more

Schering-Plough Soundly Beats Q1 Forecasts  -  Apr 20, 2007
Seeking Alpha,Schering-Plough posted better-than-expected Q1 results yesterday on the back of strong sales of rheumatoid-arthritis drug Remicade and allergy medication

New Report Assesses Chemical and Pharmaceutical Company Tanabe ...  -  Apr 20, 2007
PharmaLive.com (press release),Tanabe's pipeline is dominated by new indications and formulations for launched products, including several new indications for Remicade, chronic heart

Schering-Plough posts 55 percent rise in 1st-quarter earnings  -  Apr 19, 2007
San Diego Union Tribune,Sales of Remicade increased 34 percent to $373 million, driven by continued market growth and expanded indications for its use. The anti-inflammatory drug

Schering-Plough posts 55 percent rise in 1st-quarter earnings  -  Apr 19, 2007
International Herald Tribune,Sales of Remicade increased 34 percent to $373 million (€274.24 million), driven by continued market growth and expanded indications for its use.

Schering-Plough reports higher earnings, sales  -  Apr 19, 2007
MarketWatchSales of Remicade jumped 34% to $373 million, while Nasonex sales leapt 24% to $284 million. Revenue from the company's joint venture with Merck & Co.

European Union CHMP Recommends Approval of First and Only Biologic ...  -  Apr 2, 2007
Drug Newswire (press release),Upon receipt of the corresponding Commission Decision, REMICADE will be the first and only biologic therapy approved in the EU for the treatment of

Schering-Plough Profit Climbs Sharply  -  Apr 19, 2007
CNBC,...reported first-quarter earnings that handily beat analysts' expectations Wednesday as sales or arthritis drug Remicade jumped.

The Moose in the Room  -  Apr 16, 2007
Scientist,Centocor did $3.5 billion in sales last year, mostly on the success of its chief product, Remicade (infliximab), a tumor necrosis factor (TNF) inhibitor

European Union CHMP Recommends Approval Of First And Only Biologic ...  -  Apr 2, 2007
Medical News Today (press release),Upon receipt of the corresponding Commission Decision, REMICADE® will be the first and only biologic therapy approved in the EU for the treatment of

Crohn’s drug may go on PBS  -  Apr 20, 2007
Border Mail,The Pharmaceutical Benefits Advisory Committee has recommended the expensive drug Infliximab, or Remicade, be listed on the Pharmaceutical Benefits Scheme

Health & Medicine  -  Mar 30, 2007
Investor's Business Daily (subscription)In contrast, patients who want Johnson & Johnson's (JNJ) Remicade must travel to doctor's offices or hospitals, where nurses infuse the drug over two hours

Senior collecting tapes, games for Pediatric Center  -  Apr 18, 2007
Folsom Telegraph,Every eight weeks, however, he spends nearly an entire day at the UC Davis Pediatric Infusion Room where he receives a Remicade infusion.

Market winners and losers  -  Apr 19, 2007
Arizona Republic,The drug maker's first-quarter profit soared 55 percent amid strong demand for its Remicade drug and other products. UnitedHealth Group Inc., down $2.16 to

Nokia among Wall Street's big movers  -  Apr 19, 2007
MLive.com,The drug maker's first-quarter profit soared 55 percent amid strong demand for its Remicade drug and other products; its results beat Wall Street's forecast

Schering-Plough Peaks on 1Q Profit  -  Apr 19, 2007
Forbes,Sales of Remicade, a treatment for Crohn's Disease and arthritis, and cholesterol drugs Vytorin and Zetia drove sales up 17 percent, to $2.98 billion from

US pharma earnings in good health  -  Apr 19, 2007
MSNBCSchering-Plough was also lifted by a 34 per cent jump to $373m in sales of Remicade, its medicine for treating immune system related inflamatory disorders

Huge Numbers at Schering-Plough  -  Apr 19, 2007
TheStreet.comStockpickr) surged past Wall Street's profit estimates for the first quarter owing to big sales increases in drugs like Remicade, Nasonex and Clarinex.

Schering-Plough posts 55 percent rise in 1st-quarter earnings on ...  -  Apr 19, 2007
Therapeutics Daily (subscription) (press release),...its first-quarter profit rose 55 percent to easily beat Wall Street expectations, helped by strong demand for its Remicade drug and other products.

Abbott Profit Falls; Shares Slip on Humira Concern  -  Apr 18, 2007
Reuters.uk,N: Quote, Profile , Research) Remicade, is on track to meet its 2007 sales goal of more than $2.7 billion and might even do better, Abbott officials told

J&J, NYU charge Abbott with infringement  -  Apr 18, 2007
Chicago Sun-Times,Centocor markets a competing anti-TNF arthritis drug Remicade, which had 2006 sales of more than $3 billion. Morningstar Inc. analyst Heather Brilliant said

Getting drama treatment  -  Apr 10, 2007
Dallas Morning News (subscription),The 58-minute documentary was directed by Chris Valentino and produced by Centocor Inc., a division of Johnson & Johnson and maker of Remicade,

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),Sales of REMICADE increased 34 percent to $373 million in the first quarter of 2007, driven by growth across all indications. REMICADE is a treatment for

Novosom Acquires Exclusive Option for Antisense Inhibitors from ...  -  Apr 11, 2007
GenomicsProteomics.com (press release),...demonstrated targeted delivery to specific cell types with onset of action and greater in vivo efficacy than the anti-inflammatory blockbuster Remicade.

Competitor flourishes despite Crohn's disease  -  Apr 5, 2007
Albany Times Union,He has to be careful of his diet and sleep habits and takes the drug Remicade to modulate his immune system. Aside from that, there isn't much Zargham can

J&J reviews global ad planning and buying  -  Mar 31, 2007
Gulf News,The media agency review at J&J, which sells products ranging from sugar substitute Splenda to prescription arthritis drug Remicade, does not include the

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),Remicade is produced by Centocor, which was acquired by Johnson & Johnson for $4.9 billion. First approved in 1998 for Crohn disease, Remicade has since

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional